Archive · 18 Nov 2025
Eli Lilly's Weight Loss Drugs Boost Its Bid to Join Trillion-Dollar Club
Eli Lilly's weight loss drugs are so popular that they might make the company worth $1 trillion.
Lilly's drugs are doing better than its main competitor, Novo Nordisk.
Lilly's pill for weight loss will be cheaper and easier to make than its injection.
Lilly is also expanding into other countries.
If everything goes as planned, Lilly's drugs could make more money than any other medicine ever has.
Eli Lilly's weight loss drugs, Mounjaro and Zepbound, are driving its market value towards $1 trillion
Lilly's lead over Novo Nordisk has widened, with Lilly valued at $970 billion and Novo Nordisk at $200 billion
Lilly's pill for weight loss, set to launch, will enter a more mature market and be cheaper than injections
Lilly's international expansion, particularly in markets like Brazil and Europe, could boost global sales
Analysts expect Lilly's twin brands to generate over $40 billion in annual sales by 2026, potentially making tirzepatide the bestselling medicine in history
- Who
- Eli Lilly and Company
- What
- Is expanding its weight loss drug market and dominating it
- When
- Currently, with a potential patent cliff in the next decade
- Where
- Globally, with a focus on markets like Brazil and Europe
- Why
- To maintain a market value above $1 trillion
Investors Optimistic about Lilly's Future
Analysts Cautious about Long-term Patent Challenges
Market Growth
Investors Optimistic about Lilly's Future
Lilly's growth engine has plenty of room to keep growing
Analysts Cautious about Long-term Patent Challenges
Lilly's patent cliff in the next decade could impact its long-term ability to stay in the trillion-dollar club
- Drugs
- Mounjaro and Zepbound
- Shared Ingredient
- Tirzepatide
- Expected Annual Sales by 2026
- Over $40 billion
- Potential Future Sales
- Up to $60 billion by the end of the decade
- Main Competitor
- Novo Nordisk